Clinical Trial: Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer

U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07153965) titled 'Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer' on Aug. 24.

Brief Summary: This is an open-label, single-arm, multicenter phase II study to evaluate the safety and efficacy of sac-TMT plus Tagitanlimab in patients with PD-L1-positive locally advanced or metastatic TNBC.

Study Start Date: Sept. 01

Study Type: INTERVENTIONAL

Condition: Triple Negative Breast Cancer (TNBC) PD-L1 Positive

Intervention: DRUG: Sacituzumab Tirumotecan plus Tagitanlimab

Sacituzumab Tirumotecan 5mg/kg intravenously (IV) infusion every 2 weeks on Day 1, Tagitanlimab 900mg IV ...